Abstract
We report the first long-term follow-up of a randomized trial ( NCT04978259 ) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
【초록키워드】 COVID-19, Hospitalization, fatigue, randomized trial, Remdesivir, Symptom, outcome, hospitalized patients, Symptoms, hospitals, memory, Patient, Pain, Quality of life, long-COVID, Follow-up, Evidence, Long-term follow-up, Standard of care, confidence interval, Primary outcome, 95% CI, problem, SOC, Effect, benefit, joint, Finnish, resulting, occurred, recruited, reported, survived, 【제목키워드】 Trial, Hospitalization, Remdesivir, Randomized, COVID-19 infection, Effect,